Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Express Scripts
Cipla
Farmers Insurance
UBS
US Department of Justice
Merck
Medtronic
McKesson

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021316

« Back to Dashboard

NDA 021316 describes ALTOPREV, which is a drug marketed by Covis Pharma Bv and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the ALTOPREV profile page.

The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the lovastatin profile page.
Summary for 021316
Tradename:ALTOPREV
Applicant:Covis Pharma Bv
Ingredient:lovastatin
Patents:1
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021316
Medical Subject Heading (MeSH) Categories for 021316
Suppliers and Packaging for NDA: 021316
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316 NDA Covis Pharma 70515-628 N 70515-628-30
ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316 NDA Covis Pharma 70515-629 N 70515-629-30

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength10MG
Approval Date:Jun 26, 2002TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Mar 23, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength20MG
Approval Date:Jun 26, 2002TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 23, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength40MG
Approval Date:Jun 26, 2002TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 23, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE

Expired US Patents for NDA 021316

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
US Department of Justice
Citi
Medtronic
Express Scripts
Queensland Health
Dow
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.